Compare XEL & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | RVMD |
|---|---|---|
| Founded | 1909 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1B | 40.3B |
| IPO Year | 2003 | 2020 |
| Metric | XEL | RVMD |
|---|---|---|
| Price | $80.88 | $182.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 25 |
| Target Price | $89.82 | ★ $274.84 |
| AVG Volume (30 Days) | ★ 6.5M | 2.1M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $11,537,000,000.00 | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $10.24 | $223.88 |
| P/E Ratio | $23.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $68.72 | $63.50 |
| 52 Week High | $84.23 | $224.31 |
| Indicator | XEL | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 44.51 |
| Support Level | $76.70 | $177.62 |
| Resistance Level | $83.15 | $197.29 |
| Average True Range (ATR) | 1.57 | 9.87 |
| MACD | 0.10 | 0.35 |
| Stochastic Oscillator | 80.73 | 15.73 |
Xcel Energy manages utilities serving 3.9 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy. It plans to sell its Michigan assets in 2027.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.